Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers
Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers
复制标题
DOI：
10.4161/gmic.2.4.16108
复制
发表时间：
2011-01-01
期刊：
影响因子：
12.2
通讯作者：
Rougeot, Catherine
中科院分区：
文献类型：
--
作者：
Messaoudi, Michael;Violle, Nicolas;Rougeot, Catherine
在最近的一项临床研究中，我们在普通人群中证明，瑞士乳杆菌 R0052 和长双歧杆菌 R0175 (PF) 联合服用 30 天可降低医院焦虑和抑郁量表 (HAD) 的总体评分以及霍普金斯症状检查表 (HSCL-90) 的总体严重性指数 (HSCL-90)，这是由于躯体化、抑郁和愤怒敌意领域的分项评分下降。因此，口服PF对人类志愿者的焦虑和抑郁相关行为显示出有益的影响。从这里开始，关注这种益生菌制剂在基线尿游离皮质醇水平最低的受试者中的作用是很有趣的。本附录根据基线和随访期间感知压力量表 (PS)、HAD 和 HSCL-90 评分的变化百分比，对 25 名基线尿游离皮质醇 (UFC) 水平低于 50 ng/ml 的受试者亚群中 PF 对心理困扰的影响进行了二次分析。数据显示，PF 改善了与一般人群相同的分数（HAD 总体评分、HSCL-90 的总体严重性指数及其三个子评分，即躯体化、抑郁和愤怒-敌意），以及 PSs 评分和 HSCL-90 的其他三个子评分，即“强迫症”、“焦虑症”和“偏执狂”。此外，在 HSCL-90 中，与对照组相比，经过 PF 治疗的受试者中与焦虑和抑郁相关的因子 1 的得分随着时间的推移显着改善。额外的临床前数据表明，PF 制剂不会引起成瘾或学习和记忆障碍等副作用，因此显示出良好的安全性。提出了补充的假设作用机制来解释脑肠轴的功能，特别是益生菌与压力相关的精神病理学之间的关系，例如焦虑和抑郁。
In a recent clinical study, we demonstrated in the general population that Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (PF) taken in combination for 30 days decreased the global scores of hospital anxiety and depression scale (HADs), and the global severity index of the Hopkins symptoms checklist (HSCL-90), due to the decrease of the sub-scores of somatization, depression and angerhostility spheres. Therefore, oral intake of PF showed beneficial effects on anxiety and depression related behaviors in human volunteers. From there, it is interesting to focus on the role of this probiotic formulation in the subjects with the lowest urinary free cortisol levels at baseline.This addendum presents a secondary analysis of the effects of PF in a subpopulation of 25 subjects with urinary free cortisol (UFC) levels less than 50 ng/ml at baseline, on psychological distress based on the percentage of change of the perceived stress scale (PSs), the HADs and the HSCL-90 scores between baseline and follow-up. The data show that PF improves the same scores as in the general population (the HADs global score, the global severity index of the HSCL-90 and three of its sub-scores, i.e., somatization, depression and anger-hostility), as well as the PSs score and three other sub-scores of the HSCL-90, i.e., "obsessive compulsive," "anxiety" and "paranoidideation." Moreover, in the HSCL-90, the score of the Factor 1, related to anxiety and depression, is significantly improved over time in PF-treated subjects compared with controls.Additional preclinical data showed that PF formulation does not induce side effects such as addiction or learning and memory impairments, and therefore displays a good safety profile.Complementary hypothetical mechanisms of action are proposed to explain the functioning of the brain-gut axis, particularly the relationship between probiotics and stress-related psychopathologies, such as anxiety and depression.